|
Correlation between clinicopathological variables and survival-univariate analysis |
||||||
| RFS |
OS |
|||||
|
|
||||||
| Variables |
No. of Pt |
HR* (95% CI) |
p-value |
HR* (95% CI) |
p-value |
|
|
|
||||||
| Age |
<50 |
102 |
1 |
0.317 |
1 |
0.283 |
| ≥50 |
43 |
1.476 (0.688–3.166) |
1.831 (0.606–5.533) |
|||
| Performance |
ECOG 0–1 |
139 |
1 |
0.686 |
1 |
0.888 |
| ECOG 2 |
6 |
1.349 (0.316–5.756) |
1.160 (0.148–9.073) |
|||
| Initial clinical stage |
IIA, IIB, IIIA |
93 |
1 |
0.017 |
1 |
0.010 |
| IIIB, IIIC |
52 |
2.370 (1.116–4.815) |
4.764 (1.462–15.525) |
|||
| pCR |
No |
134 |
1 |
0.817 |
NA# |
NA# |
| Yes |
11 |
1.186 (0.281–5.005) |
||||
| Pathologic stage |
pCR~IIIA |
113 |
1 |
0.288 |
1 |
0.086 |
| IIIB, IIIC |
32 |
1.525 (0.700–3.319) |
2.608 (0.874–7.786) |
|||
| Pathologic N stage |
N0 |
42 |
1 |
0.636 |
1 |
0.566 |
| N1–3 |
103 |
0.828 (0.378–1.812) |
1.558 (0.342–7.099) |
|||
| Radiologic response |
Responder |
100 |
1 |
0.515 |
1 |
0.683 |
| Non-responder |
45 |
0.776 (0.361–1.665) |
1.258 (0.419–3.775) |
|||
| Nuclear grade |
I, II |
41 |
1 |
0.151 |
1 |
0.141 |
| III |
87 |
1.894 (0.792–4.532) |
2.689 (0.722–10.023) |
|||
| Histologic grade |
I, II |
39 |
1 |
0.020 |
1 |
0.132 |
| III |
82 |
4.159 (1.248–13.865) |
4.820 (0.621–32.387) |
|||
| ER |
Positive |
64 |
1 |
0.001 |
1 |
0.028 |
| Negative |
81 |
5.410 (2.073–14.119) |
9.921 (1.289–76.349) |
|||
| PR |
Positive |
44 |
1 |
0.005 |
1 |
0.166 |
| Negative |
101 |
7.778 (1.851–32.673) |
4.278 (0.547–33.476) |
|||
| bcl-2 |
Positive |
63 |
1 |
0.034 |
1 |
0.046 |
| Negative |
74 |
2.351 (1.068–5.175) |
4.705 (1.030–21.490) |
|||
| Ki-67 |
Low expression |
56 |
1 |
0.038 |
1 |
0.082 |
| High expression |
85 |
2.357 (1.050–5.287) |
3.263 (0.861–12.363) |
|||
| p53 |
Low expression |
67 |
1 |
0.869 |
1 |
0.670 |
| High expression |
76 |
1.063 (0.515–2.193) |
1.281 (0.410–3.998) |
|||
| c-erbB2 |
0/+/++ |
107 |
1 |
0.242 |
1 |
0.678 |
| +++ |
38 |
1.555 (0.742–3.255) |
1.273 (0.408–3.973) |
|||
| Triple negative |
No |
98 |
1 |
0.002 |
1 |
0.029 |
| Yes |
47 |
3.148 (1.539–6.441) |
3.430 (1.133–10.378) |
|||
|
RFS, relapse free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. *Hazard ratio was calculated by Cox's proportional hazard model. If the hazard ratio is greater than 1, the hazard ratio can be thought of as the average increased risk of relapse or dying at any point in time compared with the reference group (described upper line). #NA: Not available due to all censored in pCR. | ||||||
Keam et al. BMC Cancer 2007 7:203 doi:10.1186/1471-2407-7-203 |
||||||